


orum for Collaborative HIV Research

HCV TRIALS IN THE POST-APPROVAL ERA OF TELAPREVIR AND BOCEPREVIR – THE WAY FORWARD






enhancing & facilitating HIV research


FORUM MISSION

• The Forum for Collaborative HIV Research is a public/private partnership including government agencies, industry, HIV researchers and clinicians, payors, foundations and the HIV patient advocacy community.

Our mission is to facilitate and enhance HIV research.

• HIV collaborative model applied to HCV







HCV DRUG DEVELOPMENT ADVISORY GROUP (HCV DRAG)

- **Purpose**: bring together parties interested in and working in HCV drug development
 - Composition: representatives from industry, academics and regulatory agencies, community advocates

• Objectives:

- Provide scientific guidance to facilitate discussion between regulatory agencies, academia, community and industry on:
 - Clinical trial design for HCV DAA's in diverse populations
 - Consensus on appropriate methodology for HCV resistance testing in drug development
 - Sequence analysis and phenotype analysis
 - Standardization of nomenclature and definitions (with AASLD and EASL)
 - Consensus on LOD/LLOQ cutoffs for HCV viral assays for key points in therapeutic timeline
 - Educational slide deck for public use



HCV DRAG: STEERING COMMITTEE

- Michelle Berrey, MD
- Ira Jacobson, MD
- Filip Josephson, MD, PhD
- *Dale Kempf
- *Ann Kwong, PhD
- Nina Mani, PhD MPH

- Veronica Miller, PhD
- Isabel Najera, PhD
- Jules O'Rear, PhD
- *Jean-Michel Pawlotsky, MD, PhD
- Stuart Ray, MD
- Kimberly Struble, PharmD
- Tracy Swan



UPPORT LEDGME

- This meeting is supported by HCV DrAG funds
- The Forum receives funding from member pharmaceutical and diagnostic companies